Combination of curcumin and ginkgolide B inhibits cystogenesis by regulating multiple signaling pathways

Li,Yousong; Gao,Jinsheng; Yang,Xi; Li,Tao; Yang,Baoxue; Aili,Aixingzi

doi:10.3892/mmr.2021.11834

Combination of curcumin and ginkgolide B inhibits cystogenesis by regulating multiple signaling pathways

Authors:
- Yousong Li
- Jinsheng Gao
- Xi Yang
- Tao Li
- Baoxue Yang
- Aixingzi Aili
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Shanxi Bethune Hospital, Taiyuan, Shanxi 030032, P.R. China, Ping An Healthcare and Technology Company Limited (‘Ping an’), Shanghai 200120, P.R. China, Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing 100083, P.R. China, Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, P.R. China
Published online on: January 11, 2021 https://doi.org/10.3892/mmr.2021.11834
Article Number: 195
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), a common disease with a high incidence ratio of between 1/400 and 1/1,000 individuals, often results in kidney failure and even mortality. However, there are relatively few effective treatments available, and treatment is limited to lifelong hemodialysis or kidney transplant. Our previous studies have reported that curcumin (Cur) and ginkgolide B (GB) inhibited cystogenesis by regulating the Ras/ERK MAPK signaling pathway. In the present study, it was hypothesized that Cur and GB may have a synergistic effect on the inhibition of cystogenesis, and their synergistic effect may be the result of regulation of multiple signaling pathways. To assess this hypothesis, an in vitro Madin‑Darby canine kidney (MDCK) cyst model and an in vivo kidney‑specific polycystin 1 transient receptor potential channel interacting (Pkd1) knockout mouse model were established to observe the effects of the combination of Cur and GB. The cysts exposed to Cur, GB and Cur combined with GB became small thick‑walled cysts, small thin‑walled cysts and round shaped cell colonies, respectively. The combination of Cur and GB was more effective compared with either treatment alone in inhibiting cystogenesis. Additionally, to the best of our knowledge, the present study was the first to demonstrate the synergistic effect of Cur and GB on the inhibition of cystogenesis in Pkd1 knockout mice. Cur may have mediated its anti‑cyst effects by blocking EGFR/ERK1/2, JNK and PI3K/mTOR signaling pathways, while GB may have inhibited cystogenesis via the downregulation of the EGFR/ERK1/2, JNK and p38 signaling pathways. These results provide a proof‑of‑concept for application of the combination of Cur and GB in inhibiting cystogenesis in ADPKD.

View Figures

View References

1	Corradi V, Gastaldon F, Caprara C, Giuliani A, Martino F, Ferrari F and Ronco C: Predictors of rapid disease progression in autosomal dominant polycystic kidney disease. Minerva Med. 108:43–56. 2017.PubMed/NCBI
2	Chebib FT, Sussman CR, Wang X, Harris PC and Torres VE: Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol. 11:451–464. 2015. View Article : Google Scholar : PubMed/NCBI
3	Harris PC and Torres VE: Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 124:2315–2324. 2014. View Article : Google Scholar : PubMed/NCBI
4	Su Q, Hu F, Ge X, Lei J, Yu S, Wang T, Zhou Q, Mei C and Shi Y: Structure of the human PKD1/PKD2 complex. Science. 361:eaat98192018. View Article : Google Scholar : PubMed/NCBI
5	Douguet D, Patel A and Honoré E: Structure and function of polycystins: Insights into polycystic kidney disease. Nat Rev Nephrol. 15:412–422. 2019. View Article : Google Scholar : PubMed/NCBI
6	Malekshahabi T, Khoshdel Rad N, Serra AL and Moghadasali R: Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions. J Cell Physiol. 234:12451–12470. 2019. View Article : Google Scholar : PubMed/NCBI
7	Gattone VH, Chen NX, Sinders RM, Seifert MF, Duan D, Martin D, Henley C and Moe SM: Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol. 20:1527–1532. 2009. View Article : Google Scholar : PubMed/NCBI
8	Torres VE: Cyclic AMP, at the hub of the cystic cycle. Kidney Int. 66:1283–1285. 2004. View Article : Google Scholar : PubMed/NCBI
9	Calvet JP: Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol. 3:1205–1211. 2008. View Article : Google Scholar : PubMed/NCBI
10	Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, et al: Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet. 17:1505–1516. 2008. View Article : Google Scholar : PubMed/NCBI
11	Pandey P, Brors B, Srivastava PK, Bott A, Boehn SNE, Groene HJ and Gretz N: Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics. 9:6242008. View Article : Google Scholar : PubMed/NCBI
12	Yang B, Sonawane ND, Zhao D, Somlo S and Verkman AS: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol. 19:1300–1310. 2008. View Article : Google Scholar : PubMed/NCBI
13	He J, Zhou H, Meng J, Zhang S, Wang S, Shao G, Jin W, Geng X, Zhu S and Yang B: Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. Pharmacol Res. 155:1047512020. View Article : Google Scholar : PubMed/NCBI
14	Raman A, Reif GA, Dai Y, Khanna A, Li X, Astleford L, Parnell SC, Calvet JP and Wallace DP: Integrin-linked kinase signaling promotes cyst growth and fibrosis in polycystic kidney disease. J Am Soc Nephrol. 28:2708–2719. 2017. View Article : Google Scholar : PubMed/NCBI
15	Gao J, Zhou H, Lei T, Zhou L, Li W, Li X and Yang B: Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol. 654:92–99. 2011. View Article : Google Scholar : PubMed/NCBI
16	Higashihara E, Nutahara K, Okegawa T, Tanbo M, Mori H, Miyazaki I, Nitatori T and Kobayashi K: Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol. 19:746–752. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhou H, Gao J, Zhou L, Li X, Li W, Li X, Xia Y and Yang B: Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Renal Physiol. 302:F1234–F1242. 2012. View Article : Google Scholar : PubMed/NCBI
18	Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, et al: Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 377:1930–1942. 2017. View Article : Google Scholar : PubMed/NCBI
19	Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS and Wallace DP: Tolvaptan inhibits ERK-dependent cell proliferation, Cl-secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 301:F1005–F1013. 2011. View Article : Google Scholar : PubMed/NCBI
20	Tesar V, Ciechanowski K, Pei Y, Barash I, Shannon M, Li R, Williams JH, Levisetti M, Arkin S and Serra A: Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 28:3404–3413. 2017. View Article : Google Scholar : PubMed/NCBI
21	Li A, Xu Y, Fan S, Meng J, Shen X, Xiao Q, Li Y, Zhang L, Zhang X, Wu G, et al: Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD. JCI Insight. 3:e958742018. View Article : Google Scholar
22	Cabrera-López C, Bullich G, Martí T, Català V, Ballarín J, Bissler JJ, Harris PC, Ars E and Torra R: Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Med Genet. 16:392015. View Article : Google Scholar : PubMed/NCBI
23	Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, Kitamura T, Kurabayashi M, Nagai R, Higashihara E, et al: Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 11:1731–1742. 2002. View Article : Google Scholar : PubMed/NCBI
24	Raphael KL, Strait KA, Stricklett PK, Baird BC, Piontek K, Germino GG and Kohan DE: Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am J Nephrol. 30:468–473. 2009. View Article : Google Scholar : PubMed/NCBI
25	Leuenroth SJ, Bencivenga N, Chahboune H, Hyder F and Crews CM: Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant. 25:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
26	Su L, Liu L, Jia Y, Lei L, Liu J, Zhu S, Zhou H, Chen R, Lu HAJ and Yang B: Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation. Kidney Int. 92:1404–1418. 2017. View Article : Google Scholar : PubMed/NCBI
27	Zhu Y, Teng T, Wang H, Guo H, Du L, Yang B, Yin X and Sun Y: Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model. Food Funct. 9:389–396. 2018. View Article : Google Scholar : PubMed/NCBI
28	Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL and Torres VE: A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 29:2458–2470. 2018. View Article : Google Scholar : PubMed/NCBI
29	Yan FS, Sun JL, Xie WH, Shen L and Ji HF: Neuroprotective effects and mechanisms of curcumin-cu(II) and -zn(II) complexes systems and their pharmacological implications. Nutrients. 10:282017. View Article : Google Scholar
30	Zhao NJ, Liao MJ, Wu JJ and Chu KX: Curcumin suppresses Notch1 signaling: Improvements in fatty liver and insulin resistance in rats. Mol Med Rep. 17:819–826. 2018.PubMed/NCBI
31	Bandgar BP, Hote BS, Jalde SS and Gacche RN: Synthesis and biological evaluation of novel curcumin analogues as anti-inflammatory, anti-cancer and anti-oxidant agents. Med Chem Res. 21:3006–3014. 2012. View Article : Google Scholar
32	Adahoun MA, AlAkhras MH, Jaafar MS and Bououdina M: Enhanced anti-cancer and antimicrobial activities of curcumin nanoparticles. Artif Cells Nanomed Biotechnol. 45:98–107. 2017. View Article : Google Scholar : PubMed/NCBI
33	Yu W, Cao L, Zhao Y, Xiao W and Xiao B: Comparing the role of Ginkgolide B and Ginkgolide K on cultured astrocytes exposed to oxygen?glucose deprivation. Mol Med Rep. 18:4417–4427. 2018.PubMed/NCBI
34	Li R, Chen B, Wu W, Bao L, Li J and Qi R: Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factor-kappaB activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein. J Pharmacol Sci. 110:362–369. 2009. View Article : Google Scholar : PubMed/NCBI
35	Shu ZM, Shu XD, Li HQ, Sun Y, Shan H, Sun XY, Du RH, Lu M, Xiao M, Ding JH and Hu G: Ginkgolide B protects against ischemic stroke via modulating microglia polarization in mice. CNS Neurosci Ther. 22:729–739. 2016. View Article : Google Scholar : PubMed/NCBI
36	Zhou YY, Wang HY, Tang ZG and Ma DL: Two new formulae for evaluating the effectiveness of drug combinations and the revision of Bürgi's and Jin's modified Bürgi's formulae. Zhongguo Yao Li Xue Bao. 5:217–221. 1984.(In Chinese). PubMed/NCBI
37	Pan YY, Xu SP and Wei W: Effect of combined nimesulide and adriamycin on proliferation and apoptosis in hepatocellular carcinoma cell line HepG_2. Chin Pharmacol Bull. 22:884–887. 2006.
38	Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H and Serra AL: Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. Sci Rep. 8:55842018. View Article : Google Scholar : PubMed/NCBI
39	Ng TP, Chiam P, Lee T, Chua H, Lim L and Kua EH: Curry consumption and cognitive function in the elderly. Am J Epidemiol. 164:898–906. 2006. View Article : Google Scholar : PubMed/NCBI
40	Van Nong H, Hung LX, Thang PN, Chinh VD, Vu LV, Dung PT, Van Trung T and Nga PT: Fabrication and vibration characterization of curcumin extracted from turmeric (Curcuma longa) rhizomes of the northern Vietnam. Springerplus. 5:11472016. View Article : Google Scholar : PubMed/NCBI
41	Basnet P and Skalko-Basnet N: Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 6:4567–4598. 2011. View Article : Google Scholar
42	Youngjoo K: Estimation of curcumin intake in Korea based on the Korea national health and nutrition examination survey (2008–2012). Nutr Res Pract. 8:589–594. 2014. View Article : Google Scholar : PubMed/NCBI
43	Maheshwari RK, Singh AK, Gaddipati J and Srimal RC: Multiple biological activities of curcumin: A short review. Life Sci. 78:2081–2087. 2006. View Article : Google Scholar : PubMed/NCBI
44	Guan R, Zhao Y, Zhang H, Fan G, Liu X, Zhou W, Shi C, Wang J, Liu W, Liang X, et al: Draft genome of the living fossil Ginkgo biloba. Gigascience. 5:492016. View Article : Google Scholar : PubMed/NCBI
45	Wang S, Ouyang B, Aa J, Geng J, Fei F, Wang P, Wang J, Peng Y, Geng T, Li Y, et al: Pharmacokinetics and tissue distribution of ginkgolide A, ginkgolide B, and ginkgolide K after intravenous infusion of ginkgo diterpene lactones in a rat model. J Pharm Biomed Anal. 126:109–116. 2016. View Article : Google Scholar : PubMed/NCBI
46	Zheng PD, Mungur R, Zhou HJ, Hassan M, Jiang SN and Zheng JS: Ginkgolide B promotes the proliferation and differentiation of neural stem cells following cerebral ischemia/reperfusion injury, both in vivo and in vitro. Neural Regen Res. 13:1204–1211. 2018. View Article : Google Scholar : PubMed/NCBI
47	Agrawal S: Curcumin and its protective and therapeutic uses. Natl J Physiol Pharm Pharmacol. 6:1–8. 2016. View Article : Google Scholar
48	Anroopb N and Shery J: A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 7:27–31. 2016. View Article : Google Scholar : PubMed/NCBI
49	Chandran B and Goel A: A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 26:1719–1725. 2012. View Article : Google Scholar : PubMed/NCBI
50	Lyu H, Han A, Polsdofer E, Liu S and Liu B: Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B. 8:503–510. 2018. View Article : Google Scholar : PubMed/NCBI
51	Zeng F and Harris RC: The ErbB receptors and their ligands in PKD, an overview. Curr Signal Trans Ther. 5:170–180. 2010. View Article : Google Scholar
52	Zheleznova NN, Wilson PD and Staruschenko A: Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta. 1812:1301–1313. 2011. View Article : Google Scholar : PubMed/NCBI
53	Wilson SJ, Amsler K, Hyink DP, Li X, Lu W, Zhou J, Burrow CR and Wilson PD: Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia. Biochim Biophys Acta. 1762:647–655. 2006. View Article : Google Scholar : PubMed/NCBI
54	Streets AJ, Magayr TA, Huang L, Vergoz L, Rossetti S, Simms RJ, Harris PC, Peters DJM and Ong ACM: Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. Am J Physiol Renal Physiol. 312:F577–F588. 2017. View Article : Google Scholar : PubMed/NCBI
55	Torres VE, Sweeney WE, Wang X, Qian Q, Harris PC, Frost P and Avner ED: EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int. 64:1573–1579. 2003. View Article : Google Scholar : PubMed/NCBI
56	Yamaguchi T, Reif GA, Calvet JP and Wallace DP: Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 299:F944–F951. 2010. View Article : Google Scholar : PubMed/NCBI
57	Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S and Strazzabosco M: ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology. 138:360–371. e367. 2010. View Article : Google Scholar : PubMed/NCBI
58	De Stephanis L, Bonon A, Varani K, Lanza G, Gafà R, Pinton P, Pema M, Somlo S, Boletta A and Aguiari G: Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells. Clin Exp Nephrol. 21:203–211. 2017. View Article : Google Scholar : PubMed/NCBI
59	Uzgare AR, Kaplan PJ and Greenberg NM: Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate. 55:128–139. 2003. View Article : Google Scholar : PubMed/NCBI
60	Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H and Wagner EF: p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 39:741–749. 2007. View Article : Google Scholar : PubMed/NCBI
61	Nishio S, Hatano M, Nagata M, Horie S, Koike T, Tokuhisa T and Mochizuki T: Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest. 115:910–918. 2005. View Article : Google Scholar : PubMed/NCBI
62	Liu Y, Dai B, Xu C, Fu L, Hua Z and Mei C: Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. PLoS One. 6:e289152011. View Article : Google Scholar : PubMed/NCBI
63	Leonhard WN, Der Wal AV, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, Heer ED and Peters DJ: Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: In vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol. 300:F1193–F1202. 2011. View Article : Google Scholar : PubMed/NCBI
64	Aguiari G, Catizone L and Senno LD: Multidrug therapy for polycystic kidney disease: A review and perspective. Am J Nephrol. 37:175–182. 2013. View Article : Google Scholar : PubMed/NCBI
65	Lieberman HR, Kellogg MD, Fulgoni VL III and Agarwal S: Moderate doses of commercial preparations of Ginkgo biloba do not alter markers of liver function but moderate alcohol intake does: A new approach to identify and quantify biomarkers of ‘adverse effects’ of dietary supplements. Regul Toxicol Pharmacol. 84:45–53. 2017. View Article : Google Scholar : PubMed/NCBI
66	Shiao N and Chan W: Injury effects of ginkgolide B on maturation of mouse oocytes, fertilization, and fetal development in vitro and in vivo. Toxicol Lett. 188:63–69. 2009. View Article : Google Scholar : PubMed/NCBI
67	Hu Y, Mou L, Yang F, Tu H and Lin W: Curcumin attenuates cyclosporine Ainduced renal fibrosis by inhibiting hypermethylation of the klotho promoter. Mol Med Rep. 14:3229–3236. 2016. View Article : Google Scholar : PubMed/NCBI
68	Chen W, Liang Y, Xie L, Lu T, Liu X and Wang G: Pharmacokintics of the ginkgo bfollowing intravenous administration of ginkgo B emulsion in rats. Biol Pharm Bull. 30:1–5. 2007. View Article : Google Scholar : PubMed/NCBI
69	Fadus MC, Lau C, Bikhchandani J and Lynch HT: Curcumin: An age-old anti-inflammatory and anti-neoplastic agent. J Tradit Complement Med. 7:339–346. 2016. View Article : Google Scholar : PubMed/NCBI
70	Norman JT: Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta. 1812:1327–1336. 2011. View Article : Google Scholar : PubMed/NCBI